成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 154-93-8 Chemical Structure| 154-93-8

Structure of Carmustine
CAS No.: 154-93-8

Chemical Structure| 154-93-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 154-93-8

,{[proInfo.pro_purity]}

Carmustine is a cell-cycle phase nonspecific alkylating antineoplastic agent.

Synonyms: BCNU; bis-chloroethylnitrosourea; BCNU Becenum

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Ingraham, Charles H. IV ; Stalinska, Joanna ; Carson, Sean C. ; Colley, Susan B. ; Rak, Monika ; Lassak, Adam , et al.

Abstract: Glioblastomas are highly aggressive brain tumors for which therapeutic options are very limited. In a quest for new anti-glioblastoma drugs, we focused on specific structural modifications to the benzoyl-phenoxy-acetamide (BPA) structure present in a common lipid-lowering drug, fenofibrate, and in our first prototype glioblastoma drug, PP1. Here, we propose extensive computational analyses to improve the selection of the most effective glioblastoma drug candidates. Initially, over 100 structural BPA variations were analyzed and their physicochemical properties, such as water solubility (- logS), calculated partition coefficient (ClogP), probability for BBB crossing (BBB_SCORE), probability for CNS penetration (CNS-MPO) and calculated cardiotoxicity (hERG), were evaluated. This integrated approach allowed us to select pyridine variants of BPA that show improved BBB penetration, water solubility, and low cardiotoxicity. Herein the top 24 compounds were synthesized and analyzed in cell culture. Six of them demonstrated glioblastoma toxicity with IC50 ranging from 0.59 to 3.24 μM. Importantly, one of the compounds, HR68, accumulated in the brain tumor tissue at 3.7 ± 0.5 μM, which exceeds its glioblastoma IC50 (1.17 μM) by over threefold.

Alternative Products

Product Details of Carmustine

CAS No. :154-93-8
Formula : C5H9Cl2N3O2
M.W : 214.05
SMILES Code : O=C(NCCCl)N(CCCl)N=O
Synonyms :
BCNU; bis-chloroethylnitrosourea; BCNU Becenum
MDL No. :MFCD00057706
InChI Key :DLGOEMSEDOSKAD-UHFFFAOYSA-N
Pubchem ID :2578

Safety of Carmustine

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H300-H341-H350-H360-H370
Precautionary Statements:P201-P202-P260-P264-P270-P280-P301+P310+P330-P308+P311-P405-P501
Class:6.1
UN#:2811
Packing Group:Ⅱ

Related Pathways of Carmustine

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Murine B16 melanoma cells 10-30 μM 1 hour To evaluate the cytotoxicity of BCNU alone and in combination with TNF on B16 cells. Results showed BCNU reduced cell survival at 10-30 μM, with 30 μM reducing survival to 0.1 of control. Addition of TNF (2000 U/ml) further reduced survival at all BCNU doses, with 30 μM BCNU + TNF achieving one-tenth the survival of BCNU alone. PMC1971510
Neuro-2A (N2a) cells 0-240 μM 24 hours BCNU was non-toxic up to 20 μM but showed significant cytotoxicity at 80 μM (69.5%) and 240 μM (49%). PMC3655051

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice APdE9 mice (Alzheimer’s disease model) Intraperitoneal injection 0.5 mg/kg Daily for 60 days Chronic BCNU administration reduced Aβ40 levels by 75% and amyloid plaque burden by 81%. Conversely, sAPPα levels were increased by 45%. BCNU also reduced microglial activation (30% reduction in hippocampus and 44% reduction in motor cortex). PMC3655051
C57BL mice B16 melanoma model Intraperitoneal injection 35 mg/kg BCNU + 2.5×10^5 U/kg TNF Single dose BCNU (day 0), TNF once daily for 5 days To assess growth delay of B16 melanoma with combination therapy. Results showed significant prolongation of tumor doubling time in the combination group compared to monotherapy (P=0.005), without increased toxicity (weight loss or blood counts). PMC1971510
Mice Cerebellar cortical dysplasia model Intraperitoneal injection 20 mg/kg Single injection on embryonic day 13 To assess the effect of carmustine on cerebellar cortical development in mice. Results showed that carmustine treatment caused disorganization of cerebellar cortical layers, altered morphology of Bergmann glia and astrocytes, and impaired motor coordination. Additionally, spontaneous calcium signaling activity in Bergmann glia increased but with shorter duration. PMC8304447
C57BL/6 mice B16F10 xenograft model Intraperitoneal injection 35 mg/kg Every 2 days for 14 days To evaluate the antitumor effects of carmustine on B16F10 xenografts. Results showed that carmustine significantly inhibited tumor growth and enhanced the antitumor effects of BCNU and CCNU. PMC6028752
C57BlC mice GL261 glioblastoma model Intraperitoneal injection 1 mg/kg，2.5 mg/kg, 24 hours Test the therapeutic effect of RTV combined with BCNU on the GL261 glioblastoma model, found that the combination significantly prolonged mouse survival, and there was no significant difference between 1 mg/kg and 2.5 mg/kg BCNU PMC5358953

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.67mL

0.93mL

0.47mL

23.36mL

4.67mL

2.34mL

46.72mL

9.34mL

4.67mL
Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories